塞莫林纳布的药理动力学和对血的影响 临床研究中的全药理动力学
V Ramakrishnan1, B Bender, J Langenhorst
1Vidya Ramakrishnan, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, Tel: +1 (650) 225-6154, ramakrishnan.vidya@gene.com.
The journal of prevention of Alzheimer's disease
|October 1, 2024
概括
在临床研究中,阿尔茨海默病治疗药物Semorinemab在临床研究中显示出剂量比例的药理动力学和显著的血tau参与. 药物的疗效在各个患者群体中是一致的,支持其治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
背景情况:
- 赛莫里尼马布是一种研究中的单克隆抗体,向tau蛋白的N端域.
- 它目前正在临床开发中,用于阿尔茨海默病治疗.
研究的目的:
- 为了评估血清中semorinemab的药理动力学 (PK).
- 在临床研究中评估总血tau目标参与动态.
主要方法:
- 使用了一种非线性混合效应的目标中介药物排放 (TMDD) 模型.
- 分析了1期和2期临床研究的数据,涉及463名受试者.
- 在各种剂量中测量了血清赛莫林纳布和血陶的度.
主要成果:
- 赛莫林马布在健康志愿者和阿尔茨海默病患者中表现出与剂量成比例的药理动力学和可比性概况.
- 总血TAU与西莫林纳布剂量非线性增加,临床剂量时>90%的外周点接触.
- TMDD模型准确地描述了PK和tau动态,估计抗体-联体结合强度 (Kss) 为42.7nM.
结论:
- TMDD模型有效地表征了semorinemab的药理动力学和剂量依赖的tau参与.
- 剂量反应关系在健康志愿者和阿尔茨海默病的不同严重程度之间是一致的.
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
102
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
102
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170